NCT03200691 is a Phase 2 clinical trial of 3-DCRT or IMRT radiation in Esophageal Neoplasms, sponsored by Hangzhou Cancer Hospital.

Who is sponsoring NCT03200691?

NCT03200691 is sponsored by Hangzhou Cancer Hospital.

What drugs are being tested in NCT03200691?

Interventions in NCT03200691: 3-DCRT or IMRT radiation, anti-PD-1 antibody SHR-1210.

What condition does NCT03200691 study?

NCT03200691 studies Esophageal Neoplasms, Esophageal Diseases.

Is NCT03200691 still recruiting?

NCT03200691 is currently status unknown. Last updated 7 August 2017.

Last reviewed 2017-08-07 · How we verify

NCT03200691

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 7 August 2017

What this trial tests

Phase 2 trial testing 3-DCRT or IMRT radiation in Esophageal Neoplasms in 21 participants. Status unknown.

Timeline

10 August 2017

Primary endpoint
30 June 2018

1 July 2020

Quick facts

Lead sponsor	Hangzhou Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	10 August 2017
Primary completion	30 June 2018
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

3-DCRT or IMRT radiation
anti-PD-1 antibody SHR-1210 — full drug profile →

Conditions studied

Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Esophageal Diseases — all drugs for Esophageal Diseases →

Sponsor

Hangzhou Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Esophageal Neoplasms or Esophageal Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade.
Yang J, Liu X, Cao S, Dong X, et al · · 2020 · cited 134× · PMID 33014854 · DOI 10.3389/fonc.2020.01727
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W, Leng X, Mao T, Luo X, et al · · 2022 · cited 79× · PMID 35305102 · DOI 10.1093/oncolo/oyab011
Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841
Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wang R, Liu S, Chen B, Xi M. · · 2022 · cited 35× · PMID 36291954 · DOI 10.3390/cancers14205168
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer.
Yang H, Wang K, Wang T, Li M, et al · · 2020 · cited 35× · PMID 32195194 · DOI 10.3389/fonc.2020.00300
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.
Jiao R, Luo H, Xu W, Ge H. · · 2019 · cited 26× · PMID 31551657 · DOI 10.2147/ott.s214579
Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy.
Yan Y, Feng X, Li C, Lerut T, et al · · 2022 · cited 17× · PMID 36525602 · DOI 10.1097/cm9.0000000000002371
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y. · · 2023 · cited 16× · PMID 37753366 · DOI 10.3748/wjg.v29.i34.5020

Verify or expand the search:

Other recruiting trials for Esophageal Neoplasms

Currently open trials in the same condition.

NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting

Other Hangzhou Cancer Hospital trials

Trials by the same sponsor.

NCT04481100 — CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer · Phase 2 · unknown
NCT03554889 — Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells · Phase 1 · unknown
NCT03187314 — Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer · Phase 2 · completed
NCT03081715 — PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03200691 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hangzhou Cancer Hospital
Last refreshed: 7 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03200691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing